Da Inglese a Italiano Medico/Sanitario Medicina: Cardiologia Courses on Heart Failure

SGLT2 inhibitors reduce renal tubular glucose reabsorption, resulting in a reduction in blood glucose without stimulating insulin release

SGLT2i were initially developed as glucose lowering agents

In several diabetic trials, SGLT2i were observed to reduce heart failure hospitalisation

This lead to further large randomised controlled trials to determine a benefit of SGLT2i in patients with heart failure with or without diabetes

Sodium/glucose cotransporter-2 inhibitors (SGLT2i)

***Proposed mechanisms of benefit of SGLT2i***